PIPELINE

Believe in the power of true regenerative medicine

Lead Pipeline: HS-001

Lead Pipeline

Strategy: Cardiovascular disease is the leading cause of death, and Heart Failure with reduced Left Ventricular Ejection Fraction (LVEF) is the major one. We believe transplanting sufficient number of ventricular cardiomyocytes is the best possible approach to cure Heart Failure with Reduced Ejection Fraction (HFrEF).

Target indication: Target indication is HFrEF, including Dilated Cardiomyopathy (DCM), Old Myocardial Infraction (OMI) and Dilated phase of Hypertrophic Cardiomyopathy (D-HCM)

Product: allogenic iPSC-derived cardiomyocytes

Mode of Administration: Intramyocardial Injection

Development Stage: Pre-Climinal,enter FIH in 2019

PIPELINE

Research activities for following compounds

Other than our lead pipeline HS-001, intramyocardial injection of allogenic iPSC-derived cardiomyocytes, researches are ongoing such as using autologous iPSC and HLA knock-out iPSC, which are free of immune rejection. We are also conducting research with a partner to develop more convenient injection methodologies that can be used in wide range of institutions.

TECHNOLOGY

rooted in cutting-edge science
rooted in cutting-edge science

MANAGEMENT

Keiichi FUKUDA

Keiichi FUKUDA, MD/PhD/FACC

Professor and Chair, Department of Cardiology, Keio University School of Medicine
    • 1983
    • Graduated Keio University School of Medicine, Tokyo, Japan
    • 1983-1987
    • Post Graduate School, Keio University, Tokyo, Japan
    • 1987
    • PhD in Clinical Cardiology
    • 1983-1985
    • Resident in Internal Medicine, Keio University School of Medicine
    • 1985-1991
    • Resident in Cardiology, Keio University School of Medicine
    • 1991-1992
    • Growth Factor Division, National Cancer Center Research Institute
    • 1992-1994
    • Dept of Mol. Medicine, Beth Israel Hospital, Harvard Medical School
    • 1994-1995
    • Cardiovascular Research Center, University of Michigan
    • 1995-1999
    • Lecturer, Department of Cardiology, Keio University School
    • 1999-2004
    • Assistant Professor, Institute for Advanced Cardiac Therapeutics, Keio University
    • 2005-2010
    • Professor, Dept of Regenerative Medicine, Keio University
    • 2007-2017
    • Vice Dean, Keio University School of Medicine
    • 2010-present
    • Professor, Department of Cardiology, Keio University
Kikuo YASUI

Kikuo YASUI

Director, COO

Mr. Yasui joined Heartseed in 2019 as COO. Before joining Heartseed, he held various positions with increasing responsibilities at AbbVie /Abbott Japan, including Business Unit Manager, Immunology and Group Manager, Market Access. He also worked at Bain. He graduated from the Univ. of Tokyo, Pharmaceutical Sciences. (MSc)